Cold Spring Harbor, New York – September 15, 2022 – Cold Spring Harbor Laboratory Press (CSHL Press), a publisher of scientific books, journals and electronic media, today announced a new initiative to broaden access to the expanding science of glycobiology. Supported by an unconditional grant from InterVenn Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, the eBook by The essentials of glycobiology (4th edition) published by CSHL Press is made freely available to readers, ensuring equitable access to all biologists and translational researchers worldwide.
The essentials of glycobiology has become the reference manual and the key reference work in this field for the past 20 years. The 4th edition of the book, which was extensively revised earlier this year, features an expanded international editorial board and a diverse panel of contributing authors, representing a wide range of expertise in emerging fields.
Other key enhancements include an expanded focus on all lineages of life forms in nature, increased topic coverage, and in-depth attention to glycome and glycoproteome computation and exploration. Most of the characters, many of which feature illustrations by one of the book’s editors, Richard Cummings of Harvard University, are also downloadable for educational and non-profit purposes.
“The book publishers are very pleased with the opportunity to make the text available as an e-book to all interested audiences,” said Dr. Ajit Varki, Professor Emeritus, University of California, San Diego, and Editor-in-Chief. head of the textbook. “Awareness of the importance of glycobiology and glycosciences among a range of life sciences and biomedical sectors still has a long way to go, and free access to the e-book for all represents an important step in visibility for the discipline, building on the long-standing commitment of publishers to open access through the NCBI/NLM library.
“We are grateful to InterVenn for the support that enabled the distribution of The essentials of glycobiology as a free, comprehensive, downloadable e-book,” said Dr. John Inglis, Executive Director of CSHL Press. “This initiative increases the diversity of availability of this valuable content and aligns with CSHL Press’ open science goals.”
“InterVenn is privileged to be able to contribute to this important scientific and educational effort by making the leading textbook for the discipline of glycobiology freely available to all in e-book form,” said Dr. Klaus Lindpaintner, Scientist Emeritus of InterVenn and CSO. “As a pioneering company in the application of glycobiology and glycoproteomics to the clinic, we are keenly aware of the need for greater visibility and understanding of the field, especially given the growing evidence many of the pervasive impact of glycosylation on health and disease.We thank the Consortium of Glycobiology Editors of the book, as well as the team at CSHL, for this opportunity.
The e-book version of The essentials of glycobiology can be viewed at www.cshlpress.org/glycobiology.
About Cold Spring Harbor Laboratory Press
Cold Spring Harbor Laboratory Press is an internationally recognized nonprofit publisher of books, journals, and electronic media, located on Long Island, New York. Since 1933, it has promoted the advancement and dissemination of scientific knowledge in all areas of genetics and molecular biology, including cancer biology, plant science, bioinformatics and neurobiology. It is a division of Cold Spring Harbor Laboratory, an innovator in life science research and in the education of scientists, students and the public. All proceeds from sales of CSHL Press publications support research at Cold Spring Harbor Laboratory.
About InterVenn Biosciences
InterVenn is a clinical technology company that harnesses the value of glycoproteomics for the development of transformational healthcare solutions. The glycoproteome is a source of vital information about human biology that has the potential to dramatically improve patient outcomes, yet it has remained inaccessible due to its high complexity. InterVenn is pioneering a new AI-powered platform to decode and unlock the potential of the glycoproteome at a clinically meaningful scale for the first time in history. To optimize this whole new dimension of biology, the company has developed a platform capable of producing a robust pipeline of powerful clinical applications, ranging from early detection of diseases to diagnosis and potentially to therapeutics. InterVenn will help make the new era of personalized, predictive and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.